ir.ymabs.com Open in urlscan Pro
2606:4700:3035::ac43:8a3e  Public Scan

Form analysis
0 forms found in the DOM

Text Content

Skip to content
 * Our Company
   * Overview
   * Corporate Governance
     * Leadership
     * Board of Directors
   * Working at Y-mAbs
   * Careers
   * Contact us
 * Our Focus
   * Overview
   * Neuroblastoma
   * CNS/LM
   * Osteosarcoma
   * DIPG
   * Medulloblastoma
   * DSRCT
 * Our Research & Development
   * Overview
   * Platforms
     * Immunotherapy
     * Radioimmunotherapy
     * Companion Diagnostics
   * Our Pipeline
   * Partnering & Collaboration
 * Our Patient & Family Support
   * Overview
   * Access to Clinical Trials
 * For Medical Professionals
   * Overview
   * Clinical Trials
 * For Investors
   * Overview
   * Stock Information
     * Stock Quote & Chart
   * News & Presentations
     * Press Releases
     * Events
     * Presentations
   * Financial Information
     * SEC Filings
     * Annual Reports
   * Corporate Governance
     * Governance Overview
     * Leadership
     * Board of Directors
     * Committee Composition
   * Investor Resources
     * Investor FAQs
     * Email Alerts
     * Contact IR


INVESTOR OVERVIEW


INVESTOR OVERVIEW

 * 
 * Investor Relations
 * Overview


CORPORATE PROFILE

Y-mAbs Therapeutics Inc. (Y-mAbs) is a late-stage clinical biopharmaceutical
company focused on the development and commercialization of novel,
antibody-based therapeutic products for the treatment of cancer based on a range
of technologies licensed from Memorial Sloan Kettering Cancer Center. Its
mission is to become the world leader in developing better and safer
antibody-based pediatric oncology products addressing clear unmet medical needs.
Y-mAbs also seeks to advance and expand its product pipeline into certain adult
cancer indications and to leverage its extensive drug development capabilities
and platform technology towards the creation of new types of bispecific
antibodies.


STOCK QUOTE

NASDAQ: YMAB
$16.29 +0.29 (+1.81%)

Data Provided by Refinitiv. Minimum 15 minutes delayed.




NEWS RELEASES

Feb 16, 2024

Y-mAbs to Announce Fourth Quarter and Full Year 2023 Financial and Operating
Results on February 29, 2024

Learn More
Jan 02, 2024

Y-mAbs Therapeutics to Present at 42nd Annual J.P. Morgan Healthcare Conference

Learn More
Dec 13, 2023

Y-mAbs Therapeutics Added to the NASDAQ Biotechnology Index

Learn More


View All


EVENTS

Mar 1, 2024 at 8:00 AM EST

Fourth Quarter 2023 Financial and Operating Results

Learn More
Jan 10, 2024 at 5:15 PM PST

42nd Annual J.P. Morgan Healthcare Conference

Learn More
Nov 14, 2023 at 9:00 AM EST

Third Quarter 2023 Financial and Operating Results

Learn More


View All



YMABS - TOOLKIT

 * Print Page
 * Email Alerts
 * RSS Feeds

Privacy Statement
Terms of Use
Contact Us
References

© 2024 Y-mAbs Therapeutics, Inc. All rights reserved.
YMB0007_GB_v1

YOU ARE LEAVING THIS WEBSITE

×

You are about to leave ymabs.com. The link will take you to a website that may
be maintained by a third party, which is solely responsible for its content.
Y-mAbs Therapeutics, Inc provides this link as a service to its web visitors,
and is not responsible for the privacy policy or terms of use of any third-party
website.

Close Continue